In PAH, recent evidence indicates a signaling imbalance between the two principal canonical pathways, with underactive SMAD1/5/8 signaling occurring alongside overactive SMAD2/3 signaling in pulmonary arterial ECs and SMCs (13). This evidence concerns the gene SMAD2 and pulmonary arterial hypertension.